Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6P6K

Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors

Summary for 6P6K
Entry DOI10.2210/pdb6p6k/pdb
Related6P6G
DescriptorHistone-lysine N-methyltransferase SMYD3, ZINC ION, MAGNESIUM ION, ... (7 entities in total)
Functional Keywordsmethyltranserase, oncology, inhibitor, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight50590.28
Authors
Elkins, P.A.,Wang, L. (deposition date: 2019-06-04, release date: 2020-01-15, Last modification date: 2024-03-13)
Primary citationSu, D.S.,Qu, J.,Schulz, M.,Blackledge, C.W.,Yu, H.,Zeng, J.,Burgess, J.,Reif, A.,Stern, M.,Nagarajan, R.,Pappalardi, M.B.,Wong, K.,Graves, A.P.,Bonnette, W.,Wang, L.,Elkins, P.,Knapp-Reed, B.,Carson, J.D.,McHugh, C.,Mohammad, H.,Kruger, R.,Luengo, J.,Heerding, D.A.,Creasy, C.L.
Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors.
Acs Med.Chem.Lett., 11:133-140, 2020
Cited by
PubMed Abstract: We report herein the discovery of isoxazole amides as potent and selective SET and MYND Domain-Containing Protein 3 (SMYD3) inhibitors. Elucidation of the structure-activity relationship of the high-throughput screening (HTS) lead compound provided potent and selective SMYD3 inhibitors. The SAR optimization, cocrystal structures of small molecules with SMYD3, and mode of inhibition (MOI) characterization of compounds are described. The synthesis and biological and pharmacokinetic profiles of compounds are also presented.
PubMed: 32071679
DOI: 10.1021/acsmedchemlett.9b00493
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.55 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon